FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to using the preparation Infliximab as an agent regulating erythrocytes metabolism in the patients with inflammatory intestinal diseases.
EFFECT: invention provides normalising the cell metabolic processes.
1 tbl, 3 ex
Title | Year | Author | Number |
---|---|---|---|
DIAGNOSTIC TECHNIQUE FOR BRONCHIAL OBSTRUCTION ACCOMPANYING INFLAMMATORY INTESTINAL DISEASES | 2011 |
|
RU2451488C1 |
METHOD FOR PROGNOSTICATING EFFICIENCY OF THERAPY IN PATIENTS WITH NONSPECIFIC ULCERATIVE COLITIS | 1991 |
|
RU2006033C1 |
METHOD OF TREATING INFLAMMATORY INTESTINAL DISEASES | 2011 |
|
RU2463055C2 |
KOBITOLIMOD FOR USE IN TREATMENT OF INFLAMMATORY BOWEL DISEASE | 2018 |
|
RU2766356C2 |
METHOD OF TREATING PATIENTS WITH ULCERATIVE COLITIS | 2009 |
|
RU2419443C1 |
METHOD OF DETERMINING DEGREE OF INFLAMMATORY PROCESS ACTIVITY IN CASE OF NON-SPECIFIC ULCERATIVE COLITIS IN CHILDREN | 2010 |
|
RU2427322C1 |
METHOD FOR PREDICTION OF RISK OF DEVELOPING RECURRENT INFLAMMATORY INTESTINAL DISEASES | 2012 |
|
RU2517069C1 |
METHOD FOR INDIVIDUAL SENSITIVITY TO PREPARATIONS OF 5-AMINOSALYCILIC ACID (5-ASA) IN PATIENTS WITH ULCEROUS COLITIS | 2005 |
|
RU2287819C1 |
METHOD FOR TREATING ULCERATIVE COLITIS | 2000 |
|
RU2165758C1 |
METHOD OF EVALUATING EFFICIENCY OF CROHN'S DISEASE AND ULCERATIVE COLITIS TREATMENT | 2008 |
|
RU2391914C2 |
Authors
Dates
2013-07-20—Published
2011-11-18—Filed